GLPG0187 is primarily investigated for its potential therapeutic applications in the treatment of cancer. It functions as an integrin antagonist, targeting integrin receptors involved in tumor growth, angiogenesis, and metastasis. By inhibiting these receptors, it may help disrupt the signaling pathways that promote cancer progression. Research has focused on its use in preclinical models to evaluate its efficacy in reducing tumor growth and preventing the spread of cancer cells. Additionally, its role in modulating the tumor microenvironment makes it a candidate for combination therapies with other anticancer agents. Further clinical studies are necessary to determine its safety and effectiveness in human patients.